Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1994-6-2
|
| pubmed:abstractText |
Hypertrophic scars and Dupuytren's disease are characterized by the presence of modified fibroblasts or myofibroblasts which are allegedly responsible for tissue retraction and excessive connective tissue production. gamma-Interferon, a cytokine produced by T-helper lymphocytes, has been shown to decrease fibroblast replication, alpha-smooth-muscle actin (the actin isoform characterizing myofibroblasts) expression, and collagen production. We have investigated in an open pilot study the possibility that intralesional injections of gamma-interferon exert a beneficial effect on the evolution of hypertrophic scars and Dupuytren's disease. In the 14 selected patients, gamma-interferon decreased the symptoms and the size of the lesions of both diseases; in hypertrophic scars, immunofluorescence examination showed that alpha-smooth-muscle actin expression also was decreased in myofibroblasts. Moreover, in fibroblasts cultured from 4 patients with hypertrophic scars, gamma-interferon decreased replication and alpha-smooth-muscle actin expression in vitro. Our results suggest that gamma-interferon could represent a useful adjunct to the nonsurgical therapy of hypertrophic scars and Dupuytren's disease. Larger controlled clinical studies, however, should test the validity of these preliminary observations.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0032-1052
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
93
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1224-35
|
| pubmed:dateRevised |
2011-2-16
|
| pubmed:meshHeading |
pubmed-meshheading:8171142-Actins,
pubmed-meshheading:8171142-Adult,
pubmed-meshheading:8171142-Cells, Cultured,
pubmed-meshheading:8171142-Cicatrix, Hypertrophic,
pubmed-meshheading:8171142-Dupuytren Contracture,
pubmed-meshheading:8171142-Female,
pubmed-meshheading:8171142-Fibroblasts,
pubmed-meshheading:8171142-Fibroma,
pubmed-meshheading:8171142-Humans,
pubmed-meshheading:8171142-Injections, Intralesional,
pubmed-meshheading:8171142-Interferon-gamma,
pubmed-meshheading:8171142-Male,
pubmed-meshheading:8171142-Microscopy, Fluorescence,
pubmed-meshheading:8171142-Middle Aged,
pubmed-meshheading:8171142-Muscle, Smooth,
pubmed-meshheading:8171142-Myosins,
pubmed-meshheading:8171142-Pilot Projects,
pubmed-meshheading:8171142-Skin Neoplasms
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Effect of gamma-interferon on the clinical and biologic evolution of hypertrophic scars and Dupuytren's disease: an open pilot study.
|
| pubmed:affiliation |
Department of Surgery, University Hospital of Geneva, Switzerland.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|